Aktienanalyse zu Tenax Therapeutics Inc (TENX)TENXTenax Therapeutics Inc

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tenax Therapeutics Inc is not a good buy right now. The current price is $2.13, and the stock has seen a staggering 84.45% decline over the last 20 days. Furthermore, the RSI is at 29.415, indicating that the stock is oversold, but this is not a strong enough signal to warrant a buy given the recent downgrades from multiple analysts. The main risk is the company's significant net losses, with Q2 2026 net income reported at -$17,803,000, which raises concerns about its financial health and future viability.

1 analysts cover TENX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.